927079 Illumina !! - 500 Beiträge pro Seite

[covino02]

Empfohlen wurde Illumina bereits mehrfach.
Ein Nanotech-Wert mit Super Potential.

Große Umsätze bereits am Freitag-morgen geht`s weiter.

fundamental und charttechnisch ->> EIN KLARER KAUF !!

[covino02]

Na Bitte - sieht doch super aus.
Als Nächstes fällt die 6EUR-Marke und dann geht`s weiter.

Dabeibleiben lohnt sich.

[covino02]

Ausbruch gelungen-ab jetzt geht`s aufwärts

[meislo]

Um wieviel prozent wird ilmn heute steigen?
vielleicht sind 50 % drin!!!

Press Release Source: Illumina, Inc.


Illumina Completes Sale of San Diego Facilities for $42 Million and Enters into Long-Term Leaseback Arrangement
Thursday August 19, 4:20 pm ET
Sale Will Provide Net Proceeds in Excess of $15 Million


SAN DIEGO--(BUSINESS WIRE)--Aug. 19, 2004-- Illumina, Inc. (NASDAQ:ILMN - News) announced today that it has completed the sale of its San Diego facilities, consisting of several buildings and an undeveloped tract of land, and has entered into an initial 10 year lease of these facilities. Sale proceeds were $42 million. After payoff of a mortgage on the property and related transaction expenses, the Company will receive net proceeds from the sale in excess of $15 million.
"We originally purchased this property to ensure that we had ample building space on one campus to accommodate the development and manufacturing of our products," stated Jay Flatley, Illumina President and CEO. "Our manufacturing and product development processes have become so efficient, we no longer require the extra building capacity, allowing us to convert these efficiencies into $15 million of additional cash without dilution to shareholders," added Flatley.

Illumina (www.illumina.com) is developing next-generation tools that permit large-scale analysis of genetic variation and function. The Company`s proprietary BeadArray(TM) technology -- now used in leading genomics centers around the world -- provides the throughput, cost effectiveness and flexibility to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics. This information will correlate genetic variation and gene function with particular disease states, enhancing drug discovery, allowing diseases to be detected earlier and more specifically, and permitting better choices of drugs for individual patients.

gruss meislo